Overview\n\nWilson Sonsini\, one of the nation&rsquo\;s leading legal advisers to technology\, life sciences and growth companies\, returns to Iowa.\n\nChoose from three interactive sessions focused on: \n- Business formation and venture capital\n- Intellectual property\n- Regulatory strategy\n\nEach of the three sessions include:\n- Insights from Wilson Sonsini attorneys with perspectives from industry and University of Iowa leaders\n- Small-group discussions where participants can explore questions relevant to their own work\n\nAttend one\, two or all three sessions &mdash\; each is FREE and open to registered participants.
\nAgenda\n\n9:00 AM - 10:30 AM\nBusiness Formation &\; Venture Capital\nMatthew Meyer\, Philip Oettinger\, Bill Willis\nExplore the foundational building blocks necessary to turn a promising idea into a fundable company. This session will cover when to consider forming a startup\, key decisions around financing\, ownership and company structure and how to attract investors interested in investing in early-stage companies. \n\n12:30 PM - 02:00 PM\nIntellectual Property\nSara Patak\, Alex Key\, Leslie Williams\, Marie Kerbeshian\nLearn how a strategic approach to developing intellectual property can help protect discoveries and create more value as they move toward the marketplace. This session will explore key considerations around formulating patents to protect your inventions as well as understanding licensing pathways and process\, including visibility to how companies can work with UIRF (the technology transfer office) to navigate the commercialization process.\n\n2:30 PM - 04:00 PM\nRegulatory Strategy\nEva Yin\, Leslie Williams\nExplore how regulatory strategy can shape every element along the path from invention to commercialization\, particularly for life sciences and health-related technologies. This session will examine the importance of how a focus on the regulatory pathway at company outset can positively influence product development\, clinical trial strategy\, reimbursement and commercialization strategy while avoiding common regulatory pitfalls.